AVEO - アベオ・ファ―マシュ―ティカルズ (AVEO Pharmaceuticals Inc.) アベオ・ファ―マシュ―ティカルズ

 AVEOのチャート


 AVEOの企業情報

symbol AVEO
会社名 AVEO Pharmaceuticals Inc (アベオ・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アベオ・ファーマシューティカルズ(AVEO Pharmaceuticals Inc.)は癌を治療する会社であり、癌治療法の発見・開発・商業化を中心とする。同社のHuman Responseプラットホームはヒト癌の前臨床モデルを構築する方法であり、同社に癌生物学の洞察を提供し、発見とその癌治療薬の臨床開発で活用されている。平成23年、同社とAstellas Pharma Inc. (Astellas)が提携し、主要製品候補Tivozanibを提供した。Tivozanibはオフターゲット毒性を最小限に抑えながら、血管内皮増殖因子(VEGF)封鎖を最適化するように設計されたすべての3つのVEGF受容体の阻害剤である。平成24年1月、同社は腎細胞癌(RCC)の第一治療法であるグローバルのtivozanib第III相臨床試験のデータ(TIVO-1試験と呼ばれる)を公表した。   アベオ・ファ―マシュ―ティカルズは米国のバイオ医薬品メ―カ―。がんの治療法に注力した新薬の発見、開発、商業化に従事。製品候補には、ERBB3(HER3)受容体をタ―ゲットとする臨床段階モノクロ―ナル抗体である「AV-203」、肝細胞増殖因子の「Ficlatuzumab」、チロシンキナ―ゼ阻害剤の「Tivozanib」などがある。   AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.
本社所在地 One Broadway 14th Floor Cambridge MA 02142 USA
代表者氏名 Michael P. Bailey マイケル・P・ベイリー
代表者役職名 President Chief Executive Officer Director 社長兼最高経営責任者(CEO)
電話番号 +1 617-531-2130
設立年月日 37165
市場名 NASDAQ Small Cap
ipoyear 2010年
従業員数 19人
url www.aveooncology.com
nasdaq_url https://www.nasdaq.com/symbol/aveo
adr_tso
EBITDA EBITDA(百万ドル) -24.42000
終値(lastsale) 2.89
時価総額(marketcap) 343997124.83
時価総額 時価総額(百万ドル) 347.47590
売上高 売上高(百万ドル) 6.15500
企業価値(EV) 企業価値(EV)(百万ドル) 348.11690
当期純利益 当期純利益(百万ドル) -27.88200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 AVEO Pharmaceuticals Inc. revenues decreased 49% to $1.5M. Net loss decreased 88% to $5M. Revenues reflect Collaboration and licensing revenue decrease of 54% to $1.3M. Lower net loss reflects Change in fair value of PIPE warrant lia increase from $24.4M (expense) to $9.7M (income) Research and Development - Balancing val decrease of 33% to $9.9M (expense) Interest expense.

 AVEOのテクニカル分析


 AVEOのニュース

   Aveo wins dismissal of investor lawsuit over cancer drug candidate  2020/07/24 23:36:40 Reuters
Massachusetts-based drug company Aveo Pharmaceuticals has won dismissal of a proposed class action lawsuit accusing it of misleading investors about the prospects of a cancer drug it is developing.
   AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares  2020/06/19 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share. The aggregate gross proceeds to AVEO from the offering were approximately $51.1 million, before deducting underwriting discounts and commissions and offering
   AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock  2020/06/17 02:38:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to AVEO from the offering are expected to be approximately $44.6 million before deducting underwriting discounts and commissions and offering expenses. All of the shares in the offering are being sold by AVEO. AVEO has also granted the underwriters a 3
   AVEO Announces Proposed Public Offering of Common Stock  2020/06/15 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subject to market and other conditions, and there can be no assurance as to whether or wh
   Why Is AVEO (AVEO) Up 24.8% Since Last Earnings Report?  2020/05/30 15:31:33 Zacks Investment Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Aveo wins dismissal of investor lawsuit over cancer drug candidate  2020/07/24 23:36:40 Reuters
Massachusetts-based drug company Aveo Pharmaceuticals has won dismissal of a proposed class action lawsuit accusing it of misleading investors about the prospects of a cancer drug it is developing.
   AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares  2020/06/19 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share. The aggregate gross proceeds to AVEO from the offering were approximately $51.1 million, before deducting underwriting discounts and commissions and offering
   AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock  2020/06/17 02:38:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to AVEO from the offering are expected to be approximately $44.6 million before deducting underwriting discounts and commissions and offering expenses. All of the shares in the offering are being sold by AVEO. AVEO has also granted the underwriters a 3
   AVEO Announces Proposed Public Offering of Common Stock  2020/06/15 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subject to market and other conditions, and there can be no assurance as to whether or wh
   Why Is AVEO (AVEO) Up 24.8% Since Last Earnings Report?  2020/05/30 15:31:33 Zacks Investment Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   AVEO Announces Closing of Public Offering of Common Stock and Partial Exercise of Option to Purchase Additional Shares  2020/06/19 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 9,725,000 shares of its common stock, which includes the partial exercise by the underwriters of their option to purchase an additional 1,225,000 shares, at a price to the public of $5.25 per share. The aggregate gross proceeds to AVEO from the offering were approximately $51.1 million, before deducting underwriting discounts and commissions and offering
   AVEO Announces Pricing of $44.6 Million Public Offering of Common Stock  2020/06/17 02:38:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has priced its previously announced underwritten public offering of 8,500,000 shares of its common stock at a price to the public of $5.25 per share. The gross proceeds to AVEO from the offering are expected to be approximately $44.6 million before deducting underwriting discounts and commissions and offering expenses. All of the shares in the offering are being sold by AVEO. AVEO has also granted the underwriters a 3
   AVEO Announces Proposed Public Offering of Common Stock  2020/06/15 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that it has commenced an underwritten public offering of $40.0 million of shares of its common stock. In connection with the offering, AVEO intends to grant the underwriters a 30-day option to purchase up to an additional $6.0 million of shares of its common stock. All of the shares in the offering are to be sold by AVEO. The offering is subject to market and other conditions, and there can be no assurance as to whether or wh
   Why Is AVEO (AVEO) Up 24.8% Since Last Earnings Report?  2020/05/30 15:31:33 Zacks Investment Research
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   AVEO Announces Change to Virtual Annual Meeting of Stockholders  2020/05/27 20:05:00 Business Wire
BOSTON--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities, the location of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) has been changed to a virtual meeting. As previously announced, the Annual Meeting will be hel

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アベオ・ファ―マシュ―ティカルズ AVEO AVEO Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)